<DOC>
	<DOCNO>NCT00724620</DOCNO>
	<brief_summary>This study aim evaluate efficacy safety peginterferon alfa-2b plus weight-based ribavirin initial treatment chronic hepatitis C virus ( HCV ) genotype 1 patient . All patient receive peginterferon alfa-2b plus oral ribavirin 12 week . At end period , quantitative PCR use determine Early Viral Response ( EVR ) point treatment . Total treatment duration 48 week Early Responders , 72 week Slow Responders , 12 week Nonresponders .</brief_summary>
	<brief_title>PEG-IFN Alfa-2b Plus Ribavirin Treatment Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 ( Study P04511 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients give informed consent writing . Adult patient , old 18 young 65 year . Be hepatitis C treatmentnaïve patient . Patients assess entry METAVIR score fibrosis determine F2 , F3 F4 . Patients diagnose , treatment week 0 , visit 1 ( V1 ) , chronic hepatitis C determine positive HCVRNA test RTPCR ( reverse transcriptasepolymerase chain reaction ) assay . Patients F4 METAVIR score Class A score ChildPugh classification , follow criterion meet : Prothrombin time &lt; =3.0 second ; Absence ascites ; Absence encephalopathy . Patients compensate liver disease meeting follow minimum hematologic , biochemical serologic criterion : Hemoglobin : &gt; =12 g/dL woman &gt; =13 g/dL men ; Leukocyte count : &gt; =3 000/mm^3 ; Neutrophil count : &gt; =1 500/mm^3 ; Platelet count : &gt; =80 000/mm^3 ; Direct bilirubin , albumin , serum creatinine : within normal range . Patients history addiction abstain consume drug least two year . All patient must willing consume alcohol study . The investigator confirm sexually active woman childbearing age use adequate contraceptive method . Neither participate woman partner participate men shall get pregnant study . Women must get pregnant breastfeeding study period . Having participate clinical study within 30 day prior visit week 0 ( V1 ) study treatment . Suffering another liver disease chronic hepatitis C , : Hemochromatosis , alpha1 antitrypsin deficiency , Wilson 's disease , Autoimmune hepatitis , Alcoholic liver disease , Obesityinduced liver disease , Druginduced liver disease . With known coinfection HIV HBV . With evidence decompensated liver disease , history presence ascites , jaundice , bleed varix , esophageal gastric varix hepatic encephalopathy . With history hepatocellular carcinoma ( HCC ) . With preexist medical condition may interfere patient 's participation and/or conclusion study , : Clinically significant retinal anomaly , Central nervous system ( CNS ) trauma convulsive disorder , Poorly control diabetes mellitus , Autoimmune diseases ( eg , inflammatory intestinal disease [ Crohn 's disease , ulcerative colitis ] , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , clinical cryoglobulinemia vasculitis , symptomatic thyroid disorder ) , Chronic pneumopathies ( eg , chronic obstructive pulmonary disease ) , Cardiovascular dysfunction clinically significant electrocardiographic alteration within six month prior visit week 0 ( eg , angina pectoris , congestive heart failure , recent heart attack , severe hypertension significant arrhythmia ) , Suspected hypersensitivity interferon Ribavirin , Any organ transplantation , except corneal hair transplantation With sign suspect active cancer history cancer within past five year ( except basocellular skin carcinoma receive adequate treatment ) With addiction , alcoholism ( &gt; =40 g/day ) , intravenous ( IV ) drug inhale drug . Patients receive methadone , buprenorphine hydrochloride butorphanol tartrate within past two year may admit either . Suffering condition , investigator 's opinion , would either make patient inadequate admission study affect his/her participation conclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>